<DOC>
	<DOCNO>NCT00141804</DOCNO>
	<brief_summary>To study efficacy safety administration Tacrolimus combination Sirolimus prevention acute rejection patient renal transplantation</brief_summary>
	<brief_title>Efficacy Safety Sirolimus Combination With Tacrolimus</brief_title>
	<detailed_description>Basic randomize clinical trial ( multicentre ) primary KTX ass safety efficacy tac/rapa v tac/MMF regimen . Tac trough level accordance current standard arm . Steroids use individual centre protocol . Rapa trough level adjust 5-10 ng/ml . Up data ( primate clinical ) tac/rap combination available .</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>first kidney transplantation retransplantation nonrelated live donor transplantation patient &gt; 18 year patient give write consent inform female patient age parity must consent effective birth control submit negative pregnancy test relate living donation patient know HIVanamnesis patient need systemically administer immunosuppression another indication prophylaxis kidney graft rejection patient present malignant disease patient clinically significant , uncontrolled infectional disease and/or severe diarrhea , vomit active gastric ulcer patient take part clinical study past 28 day and/or receive ( receive ) medication license responsible health authority reason depend assessment physician</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2005</verification_date>
	<keyword>renal transplantation</keyword>
	<keyword>immunosuppression</keyword>
	<keyword>prevention acute rejection</keyword>
</DOC>